FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
This article was originally published in The Tan Sheet
Executive Summary
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers